more

Delcath Systems (DCTH)

(Delayed Data from NSDQ)

$10.50 USD

-0.39 (-3.58%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $10.88 +0.38 (3.62%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum C VGM

Industry Rank:

Top 32% (79 out of 250)

Industry: Medical - Instruments

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Delcath Systems, Inc. (DCTH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research Published on November 01,2024

Delcath Systems (DCTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Delcath Systems Stock Gains on Positive CHEMOSAT Melanoma Data

by Zacks Equity Research Published on September 02,2024

DCTH's study of the CHEMOSAT Hepatic Delivery System shows that the device significantly boosts survival rates in uveal melanoma patients with liver metastases, outperforming systemic therapies.

Delcath Systems, Inc. (DCTH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on August 05,2024

Delcath Systems (DCTH) delivered earnings and revenue surprises of -41.18% and 55.32%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Delcath Systems, Inc. (DCTH) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research Published on July 15,2024

Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.

DCTHNegative Net Change

Here's What Could Help Delcath Systems (DCTH) Maintain Its Recent Price Strength

by Zacks Equity Research Published on June 14,2024

Delcath Systems (DCTH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

DCTHNegative Net Change

Beat the Market Like Zacks: Goldman Sachs, Micron, Amgen in Focus

by Abhinab Dasgupta Published on June 10,2024

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Does Delcath Systems (DCTH) Have the Potential to Rally 197.87% as Wall Street Analysts Expect?

by Zacks Equity Research Published on June 03,2024

The mean of analysts' price targets for Delcath Systems (DCTH) points to a 197.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

DCTHNegative Net Change

Wall Street Analysts Predict a 201.72% Upside in Delcath Systems (DCTH): Here's What You Should Know

by Zacks Equity Research Published on May 17,2024

The mean of analysts' price targets for Delcath Systems (DCTH) points to a 201.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

DCTHNegative Net Change

What Makes Delcath Systems (DCTH) a Good Fit for 'Trend Investing'

by Zacks Equity Research Published on May 15,2024

DCTHNegative Net Change

Steris (STE) Matches Q4 Earnings Estimates

by Zacks Equity Research Published on May 08,2024

Steris (STE) delivered earnings and revenue surprises of 0% and 3.07%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

How Much Upside is Left in Delcath Systems (DCTH)? Wall Street Analysts Think 244.83%

by Zacks Equity Research Published on April 23,2024

The mean of analysts' price targets for Delcath Systems (DCTH) points to a 244.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

DCTHNegative Net Change

Can Delcath Systems (DCTH) Climb 277.73% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research Published on April 05,2024

The consensus price target hints at a 277.7% upside potential for Delcath Systems (DCTH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

DCTHNegative Net Change